ConductScience.org, home

Paper36936577

Endometrial cancer: molecular classification and future treatments.

Corr B and 3 others. BMJ Med, 2022. Cited by 76 papers, by iCite.

Cite this record

ConductScience Library. Endometrial cancer: molecular classification and future treatments. Papers, record 36936577. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36936577

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Endometrial cancer: molecular classification and future treatments.
PubMed
Journal
BMJ Med
PubMed
Year
2022
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
76
iCite
Relative citation ratio, by iCite
6.1
iCite
Revised in PubMed
2023-03-21
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Corr BBradleyhttps://orcid.org/0000-0002-6608-2585
2Cosgrove CCasey
3Spinosa DDaniel
4Guntupalli SSaketh

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References87

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
133375706HER2 Status in High-Risk Endometrial Cancers (PORTEC-3): Relationship with Histotype, Molecular Classification, and Clinical Outcomes.Cancers (Basel)2020https://conductscience.org/library/papers/33375706PubMed
210841828Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers.J Natl Cancer Inst2000https://conductscience.org/library/papers/10841828PubMed
335045221Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer.N Engl J Med2022https://conductscience.org/library/papers/35045221PubMed
427159395Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer.J Clin Invest2016https://conductscience.org/library/papers/27159395PubMed
525878334POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer.Clin Cancer Res2015https://conductscience.org/library/papers/25878334PubMed
623550210Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal.Sci Signal2013https://conductscience.org/library/papers/23550210PubMed
730415991Analysis of mutational signatures in primary and metastatic endometrial cancer reveals distinct patterns of DNA repair defects and shifts during tumor progression.Gynecol Oncol2019https://conductscience.org/library/papers/30415991PubMed
821903247The role of the phosphatidylinositol 3-kinase (PI3K) pathway in the development and treatment of uterine cancer.Gynecol Oncol2011https://conductscience.org/library/papers/21903247PubMed
931086306The proportion of endometrial cancers associated with Lynch syndrome: a systematic review of the literature and meta-analysis.Genet Med2019https://conductscience.org/library/papers/31086306PubMed
1020681032A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma.Cancer2010https://conductscience.org/library/papers/20681032PubMed
1133046573PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer.Int J Gynecol Cancer2020https://conductscience.org/library/papers/33046573PubMed
1228061006Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer.Cancer2017https://conductscience.org/library/papers/28061006PubMed
1319840887Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study.Gynecol Oncol2010https://conductscience.org/library/papers/19840887PubMed
1435658479TP53 Sequencing and p53 Immunohistochemistry Predict Outcomes When Bevacizumab Is Added to Frontline Chemotherapy in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study.J Clin Oncol2022https://conductscience.org/library/papers/35658479PubMed
1534269576Discovery of Pemigatinib: A Potent and Selective Fibroblast Growth Factor Receptor (FGFR) Inhibitor.J Med Chem2021https://conductscience.org/library/papers/34269576PubMed
1633541735Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology study.Gynecol Oncol2021https://conductscience.org/library/papers/33541735PubMed
173652025Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study.Cancer1987https://conductscience.org/library/papers/3652025PubMed
1826028255PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.N Engl J Med2015https://conductscience.org/library/papers/26028255PubMed
1931829447Clinicopathological and molecular characterisation of 'multiple-classifier' endometrial carcinomas.J Pathol2020https://conductscience.org/library/papers/31829447PubMed
2031415061Evaluation of POLE and POLD1 Mutations as Biomarkers for Immunotherapy Outcomes Across Multiple Cancer Types.JAMA Oncol2019https://conductscience.org/library/papers/31415061PubMed

See all 87 referencesDownload CSV of references

Cited by58

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 76 citations.

PMIDTitleJournalYearIn PapersSource
42793688Molecular Classification of Endometrial Cancer in the Era of Precision Oncology: Prognostic Significance, Emerging Biomarkers, and Personalized Therapeutic Strategies-A Systematic Review.Diagnostics (Basel)2026https://conductscience.org/library/papers/42793688PubMed
42621259Envafolimab - novel anti-PD-1/PD-L1 antibody in cancer treatment.Front Immunol2026https://conductscience.org/library/papers/42621259PubMed
42598125Current status and targeted therapies in endometrial cancer: Molecular classification-driven treatment strategies (Review).Oncol Lett2026https://conductscience.org/library/papers/42598125PubMed
42494604Molecular classification and immunotherapy in fertility-sparing treatment for endometrial cancer: opportunities and challenges.Front Oncol2026https://conductscience.org/library/papers/42494604PubMed
42333330Endometrial Serous Carcinoma Arising From Adenomyosis.Cureus2026https://conductscience.org/library/papers/42333330PubMed
42325921Comprehensive bioinformatics analysis of NCAPH expression and its clinical importance in endometrial cancer.Oncol Lett2026https://conductscience.org/library/papers/42325921PubMed
41806063Exploring the role of IGHV3-30 in the immune microenvironment and prognosis of uterine endometrial cancer.Discov Oncol2026https://conductscience.org/library/papers/41806063PubMed
41681828The Influence of Molecular Factors on the Effectiveness of New Therapies in Endometrial Cancer-Latest Evidence and Clinical Trials.Cancers (Basel)2026https://conductscience.org/library/papers/41681828PubMed
41595105Molecular Classification and Clinical Outcomes in Endometrial Cancer: Real-World Evidence from a Tertiary Care Center.Cancers (Basel)2026https://conductscience.org/library/papers/41595105PubMed
41516364Special Issue "Molecular Advances in Obstetrical and Gynaecological Disorders".Int J Mol Sci2026https://conductscience.org/library/papers/41516364PubMed
41514564Molecular Classification of Endometrial Carcinomas: Review and Recent Updates.Cancers (Basel)2025https://conductscience.org/library/papers/41514564PubMed
41383623Inflammation-driven mechanisms in endometrial cancer: pathways from inflammatory microenvironment remodeling to immune escape.Front Immunol2025https://conductscience.org/library/papers/41383623PubMed
41378048SAMD4B: a novel prognostic biomarker of endometrial carcinoma.Transl Cancer Res2025https://conductscience.org/library/papers/41378048PubMed
41315187Dissecting endometrial cancer complexity in response to standard and targeted therapies.Cell Death Dis2025https://conductscience.org/library/papers/41315187PubMed
41300972Association Between MMR Status and Prognostic Pathological Factors in Endometrioid Endometrial Cancer-A Single-Center Retrospective Study.Cancers (Basel)2025https://conductscience.org/library/papers/41300972PubMed
41226033Comparison of Long Non-Coding RNA Expressions in Endometrial Polyp and Endometrial Cancer Cases.Diagnostics (Basel)2025https://conductscience.org/library/papers/41226033PubMed
41211166Bispecific antibodies in the treatment of epithelial ovarian, endometrial, and cervical cancer: an overview of current applications, challenges, and emerging opportunities.Explor Target Antitumor Ther2025https://conductscience.org/library/papers/41211166PubMed
41003831LncRNA DEPDC1-AS1 drives the progression of endometrial carcinoma by regulating miR-508-3p.Discov Oncol2025https://conductscience.org/library/papers/41003831PubMed
40968748Enhancement of circular RNA 0002577 in serum exosomes in patients with endometrial cancer accelerates disease progression via general transcription factor II-I repeat domain-containing 1 (GTF2IRD1).J Gynecol Oncol2026https://conductscience.org/library/papers/40968748PubMed
40940815Integrating Multi-Omics in Endometrial Cancer: From Molecular Insights to Clinical Applications.Cells2025https://conductscience.org/library/papers/40940815PubMed

See all 58 cited byDownload CSV of cited by

Genes40

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
AKT1207PubTator's text mininghttps://conductscience.org/library/genes/207NCBI Gene
ARID1A8289PubTator's text mininghttps://conductscience.org/library/genes/8289NCBI Gene
BRCA1672PubTator's text mininghttps://conductscience.org/library/genes/672NCBI Gene
BRCA2675PubTator's text mininghttps://conductscience.org/library/genes/675NCBI Gene
CCNE1898PubTator's text mininghttps://conductscience.org/library/genes/898NCBI Gene
CD27429126PubTator's text mininghttps://conductscience.org/library/genes/29126NCBI Gene
CDK41019PubTator's text mininghttps://conductscience.org/library/genes/1019NCBI Gene
CDK61021PubTator's text mininghttps://conductscience.org/library/genes/1021NCBI Gene
CTNNB11499PubTator's text mininghttps://conductscience.org/library/genes/1499NCBI Gene
CYP19A11588PubTator's text mininghttps://conductscience.org/library/genes/1588NCBI Gene
ERBB22064PubTator's text mininghttps://conductscience.org/library/genes/2064NCBI Gene
EZH22146PubTator's text mininghttps://conductscience.org/library/genes/2146NCBI Gene
IDO13620PubTator's text mininghttps://conductscience.org/library/genes/3620NCBI Gene
IDO2169355PubTator's text mininghttps://conductscience.org/library/genes/169355NCBI Gene
KIT3815PubTator's text mininghttps://conductscience.org/library/genes/3815NCBI Gene
KRAS3845PubTator's text mininghttps://conductscience.org/library/genes/3845NCBI Gene
L1CAM3897PubTator's text mininghttps://conductscience.org/library/genes/3897NCBI Gene
MLH14292PubTator's text mininghttps://conductscience.org/library/genes/4292NCBI Gene
MSH24436PubTator's text mininghttps://conductscience.org/library/genes/4436NCBI Gene
MSH62956PubTator's text mininghttps://conductscience.org/library/genes/2956NCBI Gene

See all 40 genesDownload CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36936577

GET https://conductscience.org/api/papers/v1/36936577/references?page=2